Core Viewpoint - Kolon Biotech and Crescent have entered into a collaboration to jointly develop and commercialize new cancer treatment methods, including a novel combination therapy, involving Kolon Biotech's SKB105 and Crescent's CR-001 [1][2] Group 1: Collaboration Details - The collaboration includes global exclusive cross-licensing and joint development of SKB105 and CR-001, with Kolon Biotech granting Crescent exclusive rights for SKB105 outside the US, Europe, and Greater China, while Crescent grants Kolon Biotech exclusive rights for CR-001 in Greater China [1] - Both companies will independently develop other combination therapies for CR-001, which has shown strong anti-tumor activity in preclinical studies [1] Group 2: Financial Terms - Kolon Biotech will receive an upfront payment of $80 million from Crescent, with potential milestone payments totaling up to $1.25 billion and tiered royalties based on SKB105's net sales [2] - Conversely, Crescent will receive an upfront payment of $20 million from Kolon Biotech, with potential milestone payments of up to $30 million and tiered royalties based on CR-001's net sales [2] Group 3: Product Characteristics - SKB105 targets integrin β6 (ITGB6) and is designed to reduce off-target toxicity, with high expression in various solid tumors but low or no expression in most normal tissues, which may lower systemic toxicity and off-target risks [2] - SKB105 is an antibody-drug conjugate (ADC) that combines a fully human IgG1 monoclonal antibody targeting ITGB6 with a clinically validated cleavable linker, utilizing proprietary Kthiol irreversible conjugation technology to enhance drug stability and tumor-specific payload delivery [2] Group 4: Competitive Landscape - Pfizer's Sigvotatug vedotin, acquired through the purchase of Seagen, is currently the fastest progressing ADC targeting ITGB6, with two pivotal Phase III clinical studies initiated for non-small cell lung cancer (NSCLC) [3] - Sigvotatug vedotin has shown promising early clinical data in NSCLC and head and neck squamous cell carcinoma, with significant overall response rates and clinical outcomes reported [3] Group 5: Revenue Projections - The company expects revenues of 2.084 billion, 2.876 billion, and 4.663 billion yuan for the years 2025 to 2027, with net profits projected at -622 million, -130 million, and 561 million yuan respectively, maintaining a "buy" rating [3]
科伦博泰生物-B(06990.HK)：与CRESCENT达成合作 进入新型ADC联用下一代IO的抗肿瘤疗法浪潮